- Page 1 and 2:
Clinical Manual for Management of t
- Page 3 and 4:
Table of Contents Clinical Manual f
- Page 5 and 6:
Clinical Manual for Management of t
- Page 7 and 8:
Preface—About this Manual | Clini
- Page 9:
Previous Editions Atlanta Contribut
- Page 12 and 13:
♦ ♦ ♦ ♦ ♦ | Clinical Manu
- Page 14 and 15:
1-2 | Clinical Manual for Managemen
- Page 16 and 17:
1-4 | Clinical Manual for Managemen
- Page 18 and 19:
1-6 | Clinical Manual for Managemen
- Page 20 and 21:
1-8 | Clinical Manual for Managemen
- Page 23 and 24:
Initial Physical Examination Backgr
- Page 25 and 26:
Genitals/Rectum • Inspect the gen
- Page 27 and 28:
Initial and Interim Laboratory and
- Page 29 and 30:
Section 1—Testing and Assessment
- Page 31:
Patient Education ♦ ♦ ♦ ♦ D
- Page 34 and 35:
1-22 | Clinical Manual for Manageme
- Page 36 and 37:
1-24 | Clinical Manual for Manageme
- Page 38 and 39:
1-26 | Clinical Manual for Manageme
- Page 40 and 41:
1-28 | Clinical Manual for Manageme
- Page 42 and 43:
1-30 | Clinical Manual for Manageme
- Page 44 and 45:
1-32 | Clinical Manual for Manageme
- Page 46 and 47:
1-34 | Clinical Manual for Manageme
- Page 48 and 49:
1-36 | Clinical Manual for Manageme
- Page 51 and 52:
Section 2—Health Maintenance and
- Page 53:
References ♦ ♦ ♦ ♦ ♦ ♦
- Page 56 and 57:
2-6 | Clinical Manual for Managemen
- Page 58 and 59:
2-8 | Clinical Manual for Managemen
- Page 60 and 61:
2-10 | Clinical Manual for Manageme
- Page 62 and 63:
2-12 | Clinical Manual for Manageme
- Page 64 and 65:
2-14 | Clinical Manual for Manageme
- Page 67 and 68:
Occupational Postexposure Prophylax
- Page 69 and 70:
P: Plan Laboratory Testing Provide
- Page 71 and 72:
For hepatitis C, no recommended pro
- Page 73 and 74:
Section 2—Health Maintenance and
- Page 75 and 76:
as hepatitis C or another sexually
- Page 77 and 78:
for treatment is appropriate, and b
- Page 79 and 80:
Section 2—Health Maintenance and
- Page 81 and 82:
contact with the patient. Patients
- Page 83 and 84:
tablet daily of trimethoprim-sulfam
- Page 85 and 86:
Opportunistic Infection Prophylaxis
- Page 87 and 88:
Discontinuing Primary Prophylaxis P
- Page 89 and 90:
Latent Tuberculosis Background Late
- Page 91 and 92:
INH may cause liver toxicity and it
- Page 93:
Patient Education ♦ ♦ ♦ ♦
- Page 96 and 97:
2-46 | Clinical Manual for Manageme
- Page 98 and 99:
3-2 | Clinical Manual for Managemen
- Page 100 and 101:
3-4 | Clinical Manual for Managemen
- Page 102 and 103:
3-6 | Clinical Manual for Managemen
- Page 104 and 105:
3-8 | Clinical Manual for Managemen
- Page 106 and 107:
3-10 | Clinical Manual for Manageme
- Page 108 and 109:
3-12 | Clinical Manual for Manageme
- Page 110 and 111:
3-14 | Clinical Manual for Manageme
- Page 112 and 113:
3-16 | Clinical Manual for Manageme
- Page 114 and 115:
3-18 | Clinical Manual for Manageme
- Page 117 and 118:
Reducing Maternal-Infant HIV Transm
- Page 119 and 120:
Some states require written informe
- Page 121 and 122:
contraindicated during pregnancy be
- Page 123 and 124:
Section 3—Antiretroviral Therapy
- Page 125 and 126:
Nelfinavir (Viracept) Adequate drug
- Page 127 and 128:
Section 3—Antiretroviral Therapy
- Page 129 and 130:
Section 3—Antiretroviral Therapy
- Page 131 and 132:
Patient Education ♦ ♦ ♦ ♦
- Page 133:
♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦
- Page 136 and 137:
3-40 | Clinical Manual for Manageme
- Page 138 and 139:
3-42 | Clinical Manual for Manageme
- Page 140 and 141:
3-44 | Clinical Manual for Manageme
- Page 142 and 143:
3-46 | Clinical Manual for Manageme
- Page 144 and 145:
3-48 | Clinical Manual for Manageme
- Page 146 and 147:
3-50 | Clinical Manual for Manageme
- Page 148 and 149:
3-52 | Clinical Manual for Manageme
- Page 150 and 151:
4-2 | Clinical Manual for Managemen
- Page 152 and 153:
4-4 | Clinical Manual for Managemen
- Page 154 and 155:
4-6 | Clinical Manual for Managemen
- Page 156 and 157:
4-8 | Clinical Manual for Managemen
- Page 158 and 159:
4-10 | Clinical Manual for Manageme
- Page 160 and 161:
4-12 | Clinical Manual for Manageme
- Page 162 and 163:
4-14 | Clinical Manual for Manageme
- Page 165 and 166:
Section 4—Complications of Antire
- Page 167 and 168:
♦ ♦ ♦ Toronto General Hospita
- Page 169 and 170:
Adverse Reactions to HIV Medication
- Page 171 and 172:
♦ ♦ ♦ ♦ ♦ Vital signs: No
- Page 173 and 174:
egimen, symptoms of fatigue could i
- Page 175 and 176:
Recreational Drugs and Antiretrovir
- Page 177 and 178:
Section 4—Complications of Antire
- Page 179 and 180:
LSD, Mescaline, Psilocin, and Methy
- Page 181 and 182:
Immune Reconstitution Syndrome Back
- Page 183 and 184:
A: Assessment In the appropriate cl
- Page 185 and 186:
♦ ♦ ♦ ♦ ♦ Navas E, Martin
- Page 187 and 188:
5-2 | Clinical Manual for Managemen
- Page 189 and 190:
5-4 | Clinical Manual for Managemen
- Page 191 and 192:
5-6 | Clinical Manual for Managemen
- Page 193 and 194:
5-8 | Clinical Manual for Managemen
- Page 195 and 196:
5-10 | Clinical Manual for Manageme
- Page 197 and 198:
5-12 | Clinical Manual for Manageme
- Page 199 and 200:
5-14 | Clinical Manual for Manageme
- Page 202 and 203:
Eye Problems Background The immunos
- Page 204:
of
- Page 207 and 208:
5-22 | Clinical Manual for Manageme
- Page 210 and 211:
Fever Background Although fever may
- Page 212 and 213:
Headache Background Headache may ha
- Page 214 and 215:
Lymphadenopathy Background Lymphade
- Page 216:
Treatment Treatment will depend on
- Page 219 and 220:
5-34 | Clinical Manual for Manageme
- Page 222 and 223:
Neurologic Symptoms Background The
- Page 224 and 225:
♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦
- Page 226 and 227:
Pulmonary Symptoms Background Short
- Page 228:
Treatment Once the diagnosis is mad
- Page 231 and 232:
5-46 | Clinical Manual for Manageme
- Page 233 and 234:
5-48 | Clinical Manual for Manageme
- Page 235 and 236: 6-2 | Clinical Manual for Managemen
- Page 238 and 239: Candidiasis, Oral and Esophageal Ba
- Page 240: Maintenance therapy Use caution whe
- Page 243 and 244: 6-10 | Clinical Manual for Manageme
- Page 246 and 247: Cervical Dysplasia Background Cervi
- Page 248: Patient Education ♦ ♦ ♦ ♦ P
- Page 251 and 252: 6-18 | Clinical Manual for Manageme
- Page 254 and 255: Cryptosporidiosis Background Crypto
- Page 256: Patient Education ♦ ♦ ♦ ♦
- Page 259 and 260: 6-26 | Clinical Manual for Manageme
- Page 261 and 262: 6-28 | Clinical Manual for Manageme
- Page 263 and 264: 6-30 | Clinical Manual for Manageme
- Page 266 and 267: Gonorrhea and Chlamydia Background
- Page 268 and 269: Treatment of Gonorrhea Treatment op
- Page 270 and 271: Hepatitis B Infection Background He
- Page 272 and 273: ♦ ♦ ♦ ♦ ♦ Some patients t
- Page 274 and 275: Hepatitis C Infection Background He
- Page 276 and 277: pregnancy. Ribavirin is teratogenic
- Page 278 and 279: Herpes Simplex, Mucocutaneous Backg
- Page 280: References ♦ ♦ ♦ ♦ ♦ Cent
- Page 283 and 284: 6-50 | Clinical Manual for Manageme
- Page 285: 6-52 | Clinical Manual for Manageme
- Page 289 and 290: 6-56 | Clinical Manual for Manageme
- Page 291 and 292: 6-58 | Clinical Manual for Manageme
- Page 293 and 294: 6-60 | Clinical Manual for Manageme
- Page 295 and 296: 6-62 | Clinical Manual for Manageme
- Page 297 and 298: 6-64 | Clinical Manual for Manageme
- Page 299 and 300: 6-66 | Clinical Manual for Manageme
- Page 301 and 302: 6-68 | Clinical Manual for Manageme
- Page 303 and 304: 6-70 | Clinical Manual for Manageme
- Page 305 and 306: 6-72 | Clinical Manual for Manageme
- Page 308 and 309: Section 6—Disease-Specific Treatm
- Page 310 and 311: Table 1. World Health Organization
- Page 312: Table 3. Monitoring for Toxicity Si
- Page 315 and 316: 6-82 | Clinical Manual for Manageme
- Page 318 and 319: Pelvic Inflammatory Disease Backgro
- Page 320 and 321: Table 1. Treatment Regimens for Pel
- Page 322 and 323: Pneumocystis Pneumonia Background P
- Page 324 and 325: Table 1. Standard and Alternative P
- Page 326 and 327: Progressive Multifocal Leukoencepha
- Page 328 and 329: Seborrheic Dermatitis Background Se
- Page 330 and 331: Sinusitis Background Sinusitis is d
- Page 332 and 333: Syphilis Background Syphilis is a s
- Page 334 and 335: Treponemal antibody tests (TP-PA [T
- Page 336:
Some patients retain reactive (low-
- Page 339 and 340:
6-106| Clinical Manual for Manageme
- Page 341 and 342:
6-108| Clinical Manual for Manageme
- Page 343 and 344:
6-110| Clinical Manual for Manageme
- Page 345 and 346:
6-112| Clinical Manual for Manageme
- Page 347 and 348:
6-114| Clinical Manual for Manageme
- Page 349 and 350:
6-116| Clinical Manual for Manageme
- Page 351 and 352:
6-118| Clinical Manual for Manageme
- Page 353 and 354:
6-120| Clinical Manual for Manageme
- Page 355 and 356:
6-122| Clinical Manual for Manageme
- Page 357 and 358:
Pain Syndrome and Peripheral Neurop
- Page 359 and 360:
Pharmacologic interventions The fol
- Page 361 and 362:
Patient Education ♦ ♦ ♦ ♦
- Page 363 and 364:
Palliative Care and HIV Background
- Page 365 and 366:
GASTROINTESTINAL Nausea, vomiting
- Page 367:
Advance Care Planning Advance care
- Page 370 and 371:
8-2 | Clinical Manual for Managemen
- Page 373 and 374:
Depression Background Major depress
- Page 375 and 376:
of symptoms. The risk of recurrence
- Page 377 and 378:
Panic Disorder Background Panic dis
- Page 379:
♦ If benzodiazepines are used, th
- Page 382 and 383:
8-14 | Clinical Manual for Manageme
- Page 384 and 385:
8-16 | Clinical Manual for Manageme
- Page 386 and 387:
8-18 | Clinical Manual for Manageme
- Page 388 and 389:
8-20 | Clinical Manual for Manageme
- Page 390 and 391:
9-2 | Clinical Manual for Managemen
- Page 392 and 393:
9-4 | Clinical Manual for Managemen
- Page 395 and 396:
Sulfa Desensitization Background Tr
- Page 397 and 398:
Patient Education Background It has
- Page 399 and 400:
Web-Based Resources Background The